{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:19:07Z","timestamp":1790864347280,"version":"4.1.0"},"reference-count":52,"publisher":"American Association for Cancer Research (AACR)","issue":"18","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Activating mutations within fibroblast growth factor receptor 3 (FGFR3), a receptor tyrosine kinase, are responsible for human skeletal dysplasias including achondroplasia and the neonatal lethal syndromes, Thanatophoric Dysplasia (TD) type I and II. Several of these same FGFR3 mutations have also been identified somatically in human cancers, including multiple myeloma, bladder carcinoma, and cervical cancer. Based on reports that strongly activated mutants of FGFR3 such as the TDII (K650E) mutant signal preferentially from within the secretory pathway, the inhibitory properties of nordihydroguaiartic acid (NDGA), which blocks protein transport through the Golgi, were investigated. NDGA was able to inhibit FGFR3 autophosphorylation both in vitro and in vivo. In addition, signaling molecules downstream of FGFR3 activation such as signal transducers and activators of transcription (STAT)1, STAT3, and mitogen-activated protein kinase (MAPK) were inhibited by NDGA treatment. Using HEK293 cells expressing activated FGFR3-TDII, together with several multiple myeloma cell lines expressing activated forms of FGFR3, NDGA generally resulted in a decrease in MAPK activation by 1 hour, and resulted in increased apoptosis over 24 hours. The effects of NDGA on activated FGFR3 derivatives targeted either to the plasma membrane or the cytoplasm were also examined. These results suggest that inhibitory small molecules such as NDGA that target a specific subcellular compartment may be beneficial in the inhibition of activated receptors such as FGFR3 that signal from the same compartment. [Cancer Res 2008;68(18):7362\u201370]<\/jats:p>","DOI":"10.1158\/0008-5472.can-08-0575","type":"journal-article","created":{"date-parts":[[2008,9,15]],"date-time":"2008-09-15T04:47:54Z","timestamp":1221454074000},"page":"7362-7370","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Nordihydroguaiaretic Acid Inhibits an Activated Fibroblast Growth Factor Receptor 3 Mutant and Blocks Downstream Signaling in Multiple Myeloma Cells"],"prefix":"10.1158","volume":"68","author":[{"given":"April N.","family":"Meyer","sequence":"first","affiliation":[{"name":"Department of Chemistry and Biochemistry, Moores UCSD Cancer Center, University of California, San Diego, La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher W.","family":"McAndrew","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry, Moores UCSD Cancer Center, University of California, San Diego, La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Donoghue","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry, Moores UCSD Cancer Center, University of California, San Diego, La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2008,9,14]]},"reference":[{"key":"2022061700255270800_B1","doi-asserted-by":"crossref","unstructured":"Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science\u20082002; 298: 1912\u201334.","DOI":"10.1126\/science.1075762"},{"key":"2022061700255270800_B2","doi-asserted-by":"crossref","unstructured":"Robertson SC, Tynan JA, Donoghue DJ. RTK mutations and human syndromeswhen good receptors turn bad. Trends Genet\u20082000; 16: 265\u201371.","DOI":"10.1016\/S0168-9525(00)02021-7"},{"key":"2022061700255270800_B3","doi-asserted-by":"crossref","unstructured":"Jaye M, Schlessinger J, Dionne CA. Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction. Biochim Biophys Acta\u20081992; 1135: 185\u201399.","DOI":"10.1016\/0167-4889(92)90136-Y"},{"key":"2022061700255270800_B4","doi-asserted-by":"crossref","unstructured":"Johnson DE, Williams LT. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res\u20081993; 60: 1\u201341.","DOI":"10.1016\/S0065-230X(08)60821-0"},{"key":"2022061700255270800_B5","doi-asserted-by":"crossref","unstructured":"Bottcher RT, Niehrs C. Fibroblast growth factor signaling during early vertebrate development. Endocr Rev\u20082005; 26: 63\u201377.","DOI":"10.1210\/er.2003-0040"},{"key":"2022061700255270800_B6","doi-asserted-by":"crossref","unstructured":"Ornitz DM. FGF signaling in the developing endochondral skeleton. Cytokine Growth Factor Rev\u20082005; 16: 205\u201313.","DOI":"10.1016\/j.cytogfr.2005.02.003"},{"key":"2022061700255270800_B7","doi-asserted-by":"crossref","unstructured":"Chen L, Deng CX. Roles of FGF signaling in skeletal development and human genetic diseases. Front Biosci\u20082005; 10: 1961\u201376.","DOI":"10.2741\/1671"},{"key":"2022061700255270800_B8","doi-asserted-by":"crossref","unstructured":"Dailey L, Ambrosetti D, Mansukhani A, Basilico C. Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev\u20082005; 16: 233\u201347.","DOI":"10.1016\/j.cytogfr.2005.01.007"},{"key":"2022061700255270800_B9","doi-asserted-by":"crossref","unstructured":"Wilkie AO, Morriss-Kay GM, Jones EY, Heath JK. Functions of fibroblast growth factors and their receptors. Curr Biol\u20081995; 5: 500\u20137.","DOI":"10.1016\/S0960-9822(95)00102-3"},{"key":"2022061700255270800_B10","doi-asserted-by":"crossref","unstructured":"Tavormina PL, Shiang R, Thompson LM, et al. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat Genet\u20081995; 9: 321\u20138.","DOI":"10.1038\/ng0395-321"},{"key":"2022061700255270800_B11","doi-asserted-by":"crossref","unstructured":"Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet\u20081997; 16: 260\u20134.","DOI":"10.1038\/ng0797-260"},{"key":"2022061700255270800_B12","doi-asserted-by":"crossref","unstructured":"Richelda R, Ronchetti D, Baldini L, et al. A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood\u20081997; 90: 4062\u201370.","DOI":"10.1182\/blood.V90.10.4062"},{"key":"2022061700255270800_B13","doi-asserted-by":"crossref","unstructured":"Sibley K, Stern P, Knowles MA. Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours. Oncogene\u20082001; 20: 4416\u20138.","DOI":"10.1038\/sj.onc.1204543"},{"key":"2022061700255270800_B14","unstructured":"van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res\u20082001; 61: 1265\u20138."},{"key":"2022061700255270800_B15","doi-asserted-by":"crossref","unstructured":"Cappellen D, De Oliveira C, Ricol D, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet\u20081999; 23: 18\u201320.","DOI":"10.1038\/12615"},{"key":"2022061700255270800_B16","doi-asserted-by":"crossref","unstructured":"Rousseau F, el Ghouzzi V, Delezoide AL, et al. Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1). Hum Mol Genet\u20081996; 5: 509\u201312.","DOI":"10.1093\/hmg\/5.4.509"},{"key":"2022061700255270800_B17","doi-asserted-by":"crossref","unstructured":"Chesi M, Kuehl WM, Bergsagel PL. Recurrent immunoglobulin gene translocations identify distinct molecular subtypes of myeloma. Ann Oncol\u20082000; 11 Suppl 1: 131\u20135.","DOI":"10.1093\/annonc\/11.suppl_1.S131"},{"key":"2022061700255270800_B18","unstructured":"Lievens PM, Liboi E. The thanatophoric dysplasia type II mutation hampers complete maturation of FGF receptor 3, which activates STAT1 from the endoplasmic reticulum. J Biol Chem\u20082003; 279: 43254\u201360. Epub 2004 Aug 2."},{"key":"2022061700255270800_B19","doi-asserted-by":"crossref","unstructured":"Lievens PM, Mutinelli C, Baynes D, Liboi E. The kinase activity of fibroblast growth factor receptor 3 with activation loop mutations affects receptor trafficking and signaling. J Biol Chem\u20082004; 279: 43254\u201360.","DOI":"10.1074\/jbc.M405247200"},{"key":"2022061700255270800_B20","doi-asserted-by":"crossref","unstructured":"Lievens PM, Roncador A, Liboi E. K644E\/M FGFR3 mutants activate Erk1\/2 from the endoplasmic reticulum through FRS2 \u03b1 and PLC \u03b3-independent pathways. J Mol Biol\u20082006; 357: 783\u201392.","DOI":"10.1016\/j.jmb.2006.01.058"},{"key":"2022061700255270800_B21","doi-asserted-by":"crossref","unstructured":"Fujiwara T, Misumi Y, Ikehara Y. Dynamic recycling of ERGIC53 between the endoplasmic reticulum and the Golgi complex is disrupted by nordihydroguaiaretic acid. Biochem Biophys Res Commun\u20081998; 253: 869\u201376.","DOI":"10.1006\/bbrc.1998.9868"},{"key":"2022061700255270800_B22","doi-asserted-by":"crossref","unstructured":"Fujiwara T, Misumi Y, Ikehara Y. Direct interaction of the Golgi membrane with the endoplasmic reticulum membrane caused by nordihydroguaiaretic acid. Biochem Biophys Res Commun\u20082003; 301: 927\u201333.","DOI":"10.1016\/S0006-291X(03)00069-X"},{"key":"2022061700255270800_B23","doi-asserted-by":"crossref","unstructured":"Fujiwara T, Takami N, Misumi Y, Ikehara Y. Nordihydroguaiaretic acid blocks protein transport in the secretory pathway causing redistribution of Golgi proteins into the endoplasmic reticulum. J Biol Chem\u20081998; 273: 3068\u201375.","DOI":"10.1074\/jbc.273.5.3068"},{"key":"2022061700255270800_B24","doi-asserted-by":"crossref","unstructured":"Drecktrah D, de Figueiredo P, Mason RM, Brown WJ. Retrograde trafficking of both Golgi complex and TGN markers to the ER induced by nordihydroguaiaretic acid and cyclofenil diphenol. J Cell Sci\u20081998; 111: 951\u201365.","DOI":"10.1242\/jcs.111.7.951"},{"key":"2022061700255270800_B25","doi-asserted-by":"crossref","unstructured":"Blecha JE, Anderson MO, Chow JM, et al. Inhibition of IGF-1R and lipoxygenase by nordihydroguaiaretic acid (NDGA) analogs. Bioorg Med Chem Lett\u20082007; 17: 4026\u20139.","DOI":"10.1016\/j.bmcl.2007.04.092"},{"key":"2022061700255270800_B26","doi-asserted-by":"crossref","unstructured":"Meyer GE, Chesler L, Liu D, et al. Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells. J Cell Biochem\u20082007; 102: 1529\u201341.","DOI":"10.1002\/jcb.21373"},{"key":"2022061700255270800_B27","doi-asserted-by":"crossref","unstructured":"Youngren JF, Gable K, Penaranda C, et al. Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2\/HER2\/neu receptors and suppresses growth in breast cancer cells. Breast Cancer Res Treat\u20082005; 94: 37\u201346.","DOI":"10.1007\/s10549-005-6939-z"},{"key":"2022061700255270800_B28","doi-asserted-by":"crossref","unstructured":"Domin J, Higgins T, Rozengurt E. Preferential inhibition of platelet-derived growth factor-stimulated DNA synthesis and protein tyrosine phosphorylation by nordihydroguaiaretic acid. J Biol Chem\u20081994; 269: 8260\u20137.","DOI":"10.1016\/S0021-9258(17)37188-0"},{"key":"2022061700255270800_B29","doi-asserted-by":"crossref","unstructured":"Webster MK, D'Avis PY, Robertson SC, Donoghue DJ. Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II. Mol Cell Biol\u20081996; 16: 4081\u20137.","DOI":"10.1128\/MCB.16.8.4081"},{"key":"2022061700255270800_B30","doi-asserted-by":"crossref","unstructured":"Webster MK, Donoghue DJ. Enhanced signaling and morphological transformation by a membrane-localized derivative of the fibroblast growth factor receptor 3 kinase domain. Mol Cell Biol\u20081997; 17: 5739\u201347.","DOI":"10.1128\/MCB.17.10.5739"},{"key":"2022061700255270800_B31","doi-asserted-by":"crossref","unstructured":"Hart KC, Robertson SC, Donoghue DJ. Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation. Mol Biol Cell\u20082001; 12: 931\u201342.","DOI":"10.1091\/mbc.12.4.931"},{"key":"2022061700255270800_B32","doi-asserted-by":"crossref","unstructured":"Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA, Donoghue DJ. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene\u20082000; 19: 3309\u201320.","DOI":"10.1038\/sj.onc.1203650"},{"key":"2022061700255270800_B33","unstructured":"Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res\u20082002; 8: 945\u201354."},{"key":"2022061700255270800_B34","doi-asserted-by":"crossref","unstructured":"Deshpande VS, Kehrer JP. Oxidative stress-driven mechanisms of nordihydroguaiaretic acid-induced apoptosis in FL5.12 cells. Toxicol Appl Pharmacol\u20082006; 214: 230\u20136.","DOI":"10.1016\/j.taap.2005.12.011"},{"key":"2022061700255270800_B35","doi-asserted-by":"crossref","unstructured":"Carter GW, Young PR, Albert DH, et al. 5-lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther\u20081991; 256: 929\u201337.","DOI":"10.1016\/S0022-3565(25)23086-5"},{"key":"2022061700255270800_B36","doi-asserted-by":"crossref","unstructured":"Tang DG, Chen YQ, Honn KV. Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc Natl Acad Sci U S A\u20081996; 93: 5241\u20136.","DOI":"10.1073\/pnas.93.11.5241"},{"key":"2022061700255270800_B37","doi-asserted-by":"crossref","unstructured":"Decker P, Muller S. Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress. Curr Pharm Biotechnol\u20082002; 3: 275\u201383.","DOI":"10.2174\/1389201023378265"},{"key":"2022061700255270800_B38","doi-asserted-by":"crossref","unstructured":"Salari H, Braquet P, Borgeat P. Comparative effects of indomethacin, acetylenic acids, 15-HETE, nordihydroguaiaretic acid and BW755C on the metabolism of arachidonic acid in human leukocytes and platelets. Prostaglandins Leukot Med\u20081984; 13: 53\u201360.","DOI":"10.1016\/0262-1746(84)90102-1"},{"key":"2022061700255270800_B39","doi-asserted-by":"crossref","unstructured":"Chang J, Skowronek MD, Cherney ML, Lewis AJ. Differential effects of putative lipoxygenase inhibitors on arachidonic acid metabolism in cell-free and intact cell preparations. Inflammation\u20081984; 8: 143\u201355.","DOI":"10.1007\/BF00916090"},{"key":"2022061700255270800_B40","doi-asserted-by":"crossref","unstructured":"Tagaya M, Henomatsu N, Yoshimori T, Yamamoto A, Tashiro Y, Mizushima S. Inhibition of vesicle-mediated protein transport by nordihydroguaiaretic acid. J Biochem\u20081996; 119: 863\u20139.","DOI":"10.1093\/oxfordjournals.jbchem.a021323"},{"key":"2022061700255270800_B41","doi-asserted-by":"crossref","unstructured":"Holland JA, Goss RA, O'Donnell RW, Chang MM, Johnson DK, Ziegler LM. Low-density lipoprotein induced actin cytoskeleton reorganization in endothelial cells: mechanisms of action. Endothelium\u20082001; 8: 117\u201335.","DOI":"10.3109\/10623320109165321"},{"key":"2022061700255270800_B42","doi-asserted-by":"crossref","unstructured":"Papadogiannakis N, Barbieri B. Lipoxygenase inhibitors counteract protein kinase C mediated events in human T lymphocyte proliferation. Int J Immunopharmacol\u20081997; 19: 263\u201375.","DOI":"10.1016\/S0192-0561(97)00068-4"},{"key":"2022061700255270800_B43","doi-asserted-by":"crossref","unstructured":"Wagenknecht B, Schulz JB, Gulbins E, Weller M. Crm-A, bcl-2 and NDGA inhibit CD95L-induced apoptosis of malignant glioma cells at the level of caspase 8 processing. Cell Death Differ\u20081998; 5: 894\u2013900.","DOI":"10.1038\/sj.cdd.4400435"},{"key":"2022061700255270800_B44","doi-asserted-by":"crossref","unstructured":"Park S, Hahm ER, Lee DK, Yang CH. Inhibition of AP-1 transcription activator induces myc-dependent apoptosis in HL60 cells. J Cell Biochem\u20082004; 91: 973\u201386.","DOI":"10.1002\/jcb.10768"},{"key":"2022061700255270800_B45","doi-asserted-by":"crossref","unstructured":"Nishimura K, Tsumagari H, Morioka A, et al. Regulation of apoptosis through arachidonate cascade in mammalian cells. Appl Biochem Biotechnol\u20082002; 102\u2013103: 239\u201350.","DOI":"10.1385\/ABAB:102-103:1-6:239"},{"key":"2022061700255270800_B46","doi-asserted-by":"crossref","unstructured":"Tong WG, Ding XZ, Adrian TE. The mechanisms of lipoxygenase inhibitor-induced apoptosis in human breast cancer cells. Biochem Biophys Res Commun\u20082002; 296: 942\u20138.","DOI":"10.1016\/S0006-291X(02)02014-4"},{"key":"2022061700255270800_B47","doi-asserted-by":"crossref","unstructured":"Yoshida T, Shiraishi T, Horinaka M, et al. Lipoxygenase inhibitors induce death receptor 5\/TRAIL-R2 expression and sensitize malignant tumor cells to TRAIL-induced apoptosis. Cancer Sci\u20082007; 98: 1417\u201323.","DOI":"10.1111\/j.1349-7006.2007.00559.x"},{"key":"2022061700255270800_B48","doi-asserted-by":"crossref","unstructured":"Ryan CJ, Harzstark AH, Rosenberg J, et al. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. BJU Int\u20082008; 101: 436\u20139.","DOI":"10.1111\/j.1464-410X.2007.07330.x"},{"key":"2022061700255270800_B49","doi-asserted-by":"crossref","unstructured":"Zavodovskaya M, Campbell MJ, Maddux BA, et al. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells. J Cell Biochem\u20082007; 103: 624\u201335.","DOI":"10.1002\/jcb.21435"},{"key":"2022061700255270800_B50","doi-asserted-by":"crossref","unstructured":"Tavormina PL, Bellus GA, Webster MK, et al. A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene. Am J Hum Genet\u20081999; 64: 722\u201331.","DOI":"10.1086\/302275"},{"key":"2022061700255270800_B51","doi-asserted-by":"crossref","unstructured":"Blum G, Gazit A, Levitzki A. Substrate competitive inhibitors of IGF-1 receptor kinase. Biochemistry\u20082000; 39: 15705\u201312.","DOI":"10.1021\/bi001516y"},{"key":"2022061700255270800_B52","doi-asserted-by":"crossref","unstructured":"Kim SM, Park TW, Park JW. Effect of nordihydroguaiaretic acid on the secretion of lipoprotein lipase. J Biochem Mol Biol\u20082002; 35: 518\u201323.","DOI":"10.5483\/BMBRep.2002.35.5.518"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/18\/7362\/2595732\/7362.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/18\/7362\/2595732\/7362.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T23:00:35Z","timestamp":1738364435000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/68\/18\/7362\/541108\/Nordihydroguaiaretic-Acid-Inhibits-an-Activated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,14]]},"references-count":52,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2008,9,14]]},"published-print":{"date-parts":[[2008,9,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-08-0575","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,14]]}}}